Oncimmune Holdings PLC (LON:ONC) has received regulatory approval to sell its early stage lung cancer detector, EarlyCDT-Lung, in Israel.
Lung cancer kills more people in Israel than any other form of the disease, said the company.
On an age-standardised basis, Israel's lung cancer mortality rate is 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region.
Adam Hill, chief executive, added that the approval 'paves the way for the near-term commencement of commercial sales of EarlyCDT-Lung in the sophisticated healthcare market of Israel'.
Oncimmune already has exclusive distribution agreements in numerous countries including Germany, France, Italy and Spain, while approval for an EarlyCDT-Lung kit was recently granted in Singapore.